Excerpt
Excerpt
March 2026, Working Paper: "The global medicine-access crisis is not simply a failure to balance innovation and affordability. It reflects a deeper system in which shareholder-driven pharmaceutical governance and fragmented donor structures undermine public health and block the shift toward more equitable value creation."
Citations
Padmashree Gehl Sampath, Öner Tulum, and William Lazonick, Biopharmaceutical Innovation: Corporate Governance for Equitable Global Health (New York: Institute for New Economic Thinking, Working Paper, March 2026), https://www.ineteconomics.org/research/research-papers/biopharmaceutical-innovation-corporate-governance-for-equitable-global-health.